Related Experiment Video
Updated: Jul 17, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Mycobacterium tuberculosis: Pathogenesis and therapeutic targets.
Jiaxing Yang1, Laiying Zhang1, Wenliang Qiao2,3
1Center of Infectious Diseases and State Key Laboratory of Biotherapy, West China Hospital Sichuan University Chengdu China.
Tuberculosis (TB) treatment faces challenges from drug resistance and coinfections. This review explores Mycobacterium tuberculosis infection mechanisms and therapeutic targets, including novel host-directed therapies, for improved drug development.
Area of Science:
- Medical Microbiology
- Immunology
- Pharmacology
Background:
- Tuberculosis (TB) persists as a global health issue, exacerbated by drug resistance, coinfections (e.g., AIDS, COVID-19), and demanding treatment regimens.
- Mycobacterium tuberculosis (Mtb) employs sophisticated mechanisms to adapt to and manipulate host cellular processes during infection.
Purpose of the Study:
- To review the pathogenesis of TB infection, identify key therapeutic targets, and analyze existing and emerging modulators.
- To highlight the potential of host-directed therapy (HDT) as a complementary strategy to conventional antitubercular agents.
Main Methods:
- Comprehensive literature review of TB pathogenesis, therapeutic targets, and drug development.
- Analysis of first-line medications, drugs in clinical trials, and preclinical candidates.
- Evaluation of host-directed therapy approaches targeting immune response and immunopathology.
Main Results:
- Identified critical biological targets within Mtb and host-pathogen interactions.
- Summarized the landscape of current and investigational anti-TB drugs.
- Emphasized the promise of HDT in disrupting Mtb's manipulation of host defenses.
Conclusions:
- Understanding Mtb infection mechanisms and host-pathogen interactions is crucial for innovative TB treatment.
- Host-directed therapies offer a promising avenue to enhance treatment efficacy by bolstering host immunity and mitigating immunopathology.
- This review provides insights for advancing future anti-TB drug discovery and development efforts.
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

